Amgen Inc. (AMGN)
Wide Trading Range For Amgen Stock Makes This Option Shine
Even though Amgen is weak below the 200-day line, there's still a way to profit. The post Wide Trading Range For Amgen Stock Makes This Option Shine appeared first on Investor's Business Daily.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?
Shares of Amgen (AMGN 0.02%) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market rose nearly 3% in the same period. The clear culprit for the drop is, quite regrettably for shareholders, an unintentional disclosure of clinical trial information that the market found to be rather unappetizing.
AMGN Stock Down Despite Strong Data From Obesity Drug Study
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.
Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You
Amgen's MariTide shows up to 20% weight loss in Phase II, leaving room for improvement beyond 52 weeks, as weight loss did not plateau. GI side effects are a concern, but Amgen plans to address them through dose escalation strategies. The convenience of monthly or less frequent dosing leads to a differentiated profile. MariTide's potential as the first monthly treatment for type 2 diabetes enhances its competitive edge.
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Shares of Amgen (AMGN -4.76%) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.
Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond
Piper Sandler's Christopher Raymond joins 'Fast Money' to talk Amgen's stock sinking on GLP-1 results.
Amgen: MariTide Underwhelms, But There Are Ways To Win
Shares of Amgen fell after the company reported underwhelming phase 2 data with weight loss up to 20% in obese patients after 52 weeks of treatment. The results underperformed Street expectations. I believe the data the company reported today is not as bad as the market reaction suggests.
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations
Amgen (AMGN) shares tanked Tuesday after results from a test of the biotech's experimental weight-loss drug came in below expectations.
Chart of the Day: Amgen
Amgen on pace for its worst day since October of 2000. It's our Chart of the Day.
Amgen tumbles to year's low despite weightloss trial success
Amgen Inc (NASDAQ:AMGN, ETR:AMG) shares tumbled 11.6% to a year's low after results of a trial for its potential weight-loss drug showed it helped overweight or obese people lose up 20% of weight over a year. The Phase II study showed MariTide enabled up to around 20% average loss of weight without a plateau, with the company saying it is the first obesity treatment at this clinical stage with monthly or less frequent dosing to demonstrate such effective weight-loss capabilities safely.
Cramer's Stop Trading: Amgen
CNBC's Jim Cramer explains why he is keeping an eye on shares of Amgen.
